• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Provident Financial Services

Provident Financial Services

Provident Financial Services Inc PFS

Last Price$25.87Day Change (%)0.90%
Open Price$25.68Day Change ($)0.23
Day Range25.63–26.0052-Week Range20.73–28.92

As of Fri 9/22/2017 5:11:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. U.S. FDA Approves New Indication for Ipsen's Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome

    U.S. FDA Approves New Indication for Ipsen's Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome

  2. Clovis Oncology’s Rucaparib ARIEL3 Study Data Published in The Lancet

    Clovis Oncology’s Rucaparib ARIEL3 Study Data Published in The Lancet

  3. TMAC Provides Operational Update and Results of Drilling

    TMAC Provides Operational Update and Results of Drilling

  4. Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017

    Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017

  5. Ipsen and Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017

    Ipsen and Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017

  6. Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017

    Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017

  7. Merck’s KEYTRUDA® (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, ...

    Merck’s KEYTRUDA® (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Post-Platinum Failure

  8. Dominion Diamond Reports Fiscal 2018 Second Quarter Results

    Dominion Diamond Reports Fiscal 2018 Second Quarter Results

  9. New Data for Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma

    New Data for Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma

  10. CheckMate -214 Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit in Patients with Previously Untreated Advanced or Metastatic Renal Cell ...

    CheckMate -214 Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

12345

©2017 Morningstar Advisor. All right reserved.